Genomic correlates of clinical CAR T cell activity
Science Immunology · 24.07.2026 · 11 (121)
DOI: 10.1126/sciimmunol.aef4134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, erschienen am 24.07.2026. Verfasst von Mark B Leick und 30 weiteren Autor:innen. Beteiligte Einrichtung: Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes, Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 109 Literaturangaben.
Abstract (Originalsprache)
Germline variants influence immune checkpoint inhibitor responses, but their role in engineered immune cell therapies, such as chimeric antigen receptor T cells (CAR T cells), remains unclear. We integrated whole germline sequencing from patients with lymphoma treated with axicabtagene ciloleucel CAR T cell products in the ZUMA-1 and ZUMA-7 clinical trials with detailed biomarker and functional analyses to identify variants influencing clinical toxicity and pharmacokinetics. Putative deleterious variants in STXBP2 ( syntaxin binding protein 2 ) were enriched among patients with toxicity in ZUMA-1, although not confirmed in ZUMA-7. Mechanistically, STXBP2- deficient or variant-expressing T cells triggered increased inflammatory cytokine production and macrophage activation. Conversely, variants in ADAMTSL3 , a TGFβ (transforming growth factor–β) signaling regulator, correlated with protection from toxicity across both trials. Furthermore, variants in PTPN22 , a negative regulator of T cell receptor signaling, strongly associated with enhanced CAR T cell expansion, a key determinant of efficacy. Together, these findings demonstrate that germline genetics shape the safety and activity of engineered immune cell therapies, affecting future design and patient management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
- Harvard Medical School, Boston, MA 02115, USA.
- Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA 02114, USA.
- Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA.
ORCID-Profile: Mark B Leick, Baihe Sun, Filippo Birocchi, Kathleen M E Gallagher, Harrison J Silva, Rebecca C Larson, Tyler M Chinsky, Hoyin Chu, Michael C Kann, Sabrina Camp, Riaz Gillani, Stefanie R Bailey, Charlotte E Graham, Max Jan, Nicholas S Moore, Nora Horick, Justin Budka, Chad M Williams, Rhine R Shen, Eliezer Van Allen, Marcela V Maus
Zitieren
APA
Leick, M. B., Sun, B., Birocchi, F., Gallagher, K. M. E., Bratt, A., Han, S., Martin, G., Silva, H. J., Larson, R. C., Chinsky, T. M., Chu, H., Reilly, C. R., Kann, M. C., Choi, B. D., Camp, S., Gillani, R., Phillips, M., Kienka, T., Bailey, S. R., …, & Maus, M. V. (2026). Genomic correlates of clinical CAR T cell activity. Science Immunology, 11(121). https://doi.org/10.1126/sciimmunol.aef4134
Vancouver
Leick MB, Sun B, Birocchi F, Gallagher KME, Bratt A, Han S, et al. Genomic correlates of clinical CAR T cell activity. Science Immunology. 2026;11(121). doi:10.1126/sciimmunol.aef4134
BibTeX
@article{Leick2026,
author = {Leick, Mark B and Sun, Baihe and Birocchi, Filippo and Gallagher, Kathleen M E and Bratt, Alexandra and Han, Seunghun and Martin, Grace and Silva, Harrison J and Larson, Rebecca C and Chinsky, Tyler M and Chu, Hoyin and Reilly, Christopher R and Kann, Michael C and Choi, Bryan D and Camp, Sabrina and Gillani, Riaz and Phillips, Merle and Kienka, Tamina and Bailey, Stefanie R and Graham, Charlotte E and Jan, Max and Moore, Nicholas S and Horick, Nora and Budka, Justin and Filosto, Simone and Williams, Chad M and Hosseini Rad, Ali and Shen, Rhine R and Van Allen, Eliezer and AlDubayan, Saud and Maus, Marcela V},
title = {Genomic correlates of clinical CAR T cell activity},
journal = {Science Immunology},
year = {2026},
volume = {11},
number = {121},
doi = {10.1126/sciimmunol.aef4134}
}
EUVIMED